Antisense oligonucleotide treatment produces a type I interferon response that protects against diet-induced obesity

Antisense oligonucleotide treatment produces a type I interferon response that protects against diet-induced obesity

Objective: In mouse models, deficiency of TTC39B (T39) decreases hepatic lipogenic gene expression and protects against diet-induced steatohepatitis. While assessing the therapeutic potential of antisense oligonucleotides (ASOs) targeting T39, we discovered an unexpected weight loss phenotype. The o...

Full description

Bibliographic Details
Main Authors:	Kristin M. McCabe, Joanne Hsieh, David G. Thomas, Matthew M. Molusky, Liana Tascau, Jun B. Feranil, Li Qiang, Anthony W. Ferrante, Jr., Alan R. Tall
Format:	Article
Language:	English
Published:	Elsevier 2020-04-01
Series:	Molecular Metabolism
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877820300181

Similar Items

Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease
by: Michael F. Keating, et al.
Published: (2022-01-01)

Pharmacokinetics of antisense oligonucleotide drugs
by: M. R. Khaitov, et al.
Published: (2013-04-01)

Tissue pharmacokinetics of antisense oligonucleotides
by: Erica Bäckström, et al.
Published: (2024-03-01)

Selective targeting of MYC by antisense oligonucleotides
by: Gill, Taylor Elizabeth
Published: (2018)

Towards understanding and applications of antisense oligonucleotides
by: Nguyen, Le Tuan Anh
Published: (2020)

Tofersen and other antisense oligonucleotides in ALS
by: Albert Ludolph, et al.
Published: (2025-01-01)

Antisense Oligonucleotides: Concepts and Pharmaceutical Applications
by: Ariana Araya, et al.
Published: (2023-02-01)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
by: Saumya Jani, et al.
Published: (2021-04-01)

In-silico study of antisense oligonucleotide antibiotics
by: Erica S. Chen, et al.
Published: (2023-11-01)

Wrangling RNA: Antisense oligonucleotides for neurological disorders
by: Talbot, K, et al.
Published: (2019)

Antisense oligonucleotides and their applications in rare neurological diseases
by: Simon McDowall, et al.
Published: (2024-09-01)

Nonviral delivery systems for antisense oligonucleotide therapeutics
by: Si Huang, et al.
Published: (2022-09-01)

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
by: Maria Gagliardi, et al.
Published: (2021-04-01)

Antisense Oligonucleotide-Based Therapy of Viral Infections
by: Woan-Yuh Tarn, et al.
Published: (2021-11-01)

Antisense oligonucleotide therapy for KCNT1 encephalopathy
by: Lisseth Estefania Burbano, et al.
Published: (2022-12-01)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish.
by: Andrea Pauli, et al.
Published: (2015-01-01)

CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
by: Taesik Gwag, et al.
Published: (2023-02-01)

Optimizing tissue-specific antisense oligonucleotide-peptide conjugates.
by: Betts, C, et al.
Published: (2012)

Discovering antisense reagents by hybridization of RNA to oligonucleotide arrays.
by: Southern, E, et al.
Published: (1997)

Selecting effective antisense reagents on combinatorial oligonucleotide arrays.
by: Milner, N, et al.
Published: (1997)

OPTIMIZING THE DESIGN OF ANTISENSE THERAPEUTICS USING OLIGONUCLEOTIDE ARRAYS
by: Casegreen, S, et al.
Published: (1994)

Engineering antisense oligonucleotides as a tool in synthetic biology.
by: Chng, Si Hui.
Published: (2013)

Antisense oligonucleotides: the next frontier for treatment of neurological disorders
by: Rinaldi, C, et al.
Published: (2017)

Quantitative fluorescence imaging of antisense oligonucleotide mediated knockdown
by: Chan, Nicholas Zhen Woon
Published: (2024)

Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01)

Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis
by: Daisuke Ito, et al.
Published: (2024-12-01)

Antisense oligonucleotides provide optimism to the therapeutic landscape for tauopathies
by: Glenn A. Harris, et al.
Published: (2025-03-01)

Splice-switching antisense oligonucleotides for pediatric neurological disorders
by: Xiaochang Zhang
Published: (2024-07-01)

Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids
by: Sarah Diermeier, et al.
Published: (2017-08-01)

Progress in the Treatment of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
by: XU Tingting, et al.
Published: (2022-04-01)

The Evolution of Antisense Oligonucleotide Chemistry—A Personal Journey
by: Sudhir Agrawal
Published: (2021-05-01)

Antisense oligonucleotides: a novel Frontier in pharmacological strategy
by: D. Collotta, et al.
Published: (2023-11-01)

Antisense oligonucleotide is a promising intervention for liver diseases
by: Kailing Lu, et al.
Published: (2022-12-01)

Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice
by: Karah Nazor Friberg, et al.
Published: (2012-01-01)

Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities
by: Jenny Lange, et al.
Published: (2022-06-01)

Improving Cardiac Delivery of Antisense Oligonucleotides with Peptidomimetic Targeting Agents
by: Antilla, Sarah An-ning
Published: (2023)

Selective targeting of MYC mRNA by stabilized antisense oligonucleotides
by: Gill, Taylor, et al.
Published: (2024)

Perfluoroaryl Bicyclic Cell-Penetrating Peptides for Delivery of Antisense Oligonucleotides
by: Wolfe, Justin, et al.
Published: (2020)

Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.
by: Koo, T, et al.
Published: (2013)

Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma
by: Alexandre Khuu, et al.
Published: (2024-11-01)